蛋白激酶B
PI3K/AKT/mTOR通路
巴基斯坦卢比
LY294002型
癌症研究
厌氧糖酵解
糖酵解
生物
丙酮酸激酶
细胞凋亡
信号转导
化学
细胞生物学
生物化学
酶
作者
Na‐Ri Shin,Hyo‐Jung Lee,Deok Yong Sim,Eunji Im,Ji Eon Park,Woon Yi Park,Ah Reum Cho,Bum Sang Shim,Sung‐Hoon Kim
摘要
Since the AKT/mammalian target of rapamycin (mTOR)/c‐Myc signaling plays a pivotal role in the modulation of aerobic glycolysis and tumor growth, in the present study, the role of AKT/mTOR/c‐Myc signaling in the apoptotic effect of Compound K (CK), an active ginseng saponin metabolite, was explored in HepG2 and Huh7 human hepatocellular carcinoma cells (HCCs). Here, CK exerted significant cytotoxicity, increased sub‐G1, and attenuated the expression of pro‐Poly (ADP‐ribose) polymerase (pro‐PARP) and Pro‐cysteine aspartyl‐specific protease (pro‐caspase3) in HepG2 and Huh7 cells. Consistently, CK suppressed AKT/mTOR/c‐Myc and their downstreams such as Hexokinase 2 (HK2) and pyruvate kinase isozymes M2 (PKM2) in HepG2 and Huh7 cells. Additionally, CK reduced c‐Myc stability in the presence or absence of cycloheximide in HepG2 cells. Furthermore, AKT inhibitor LY294002 blocked the expression of p‐AKT, c‐Myc, HK2, PKM2, and pro‐cas3 in HepG2 cells. Pyruvate blocked the ability of CK to inhibit p‐AKT, p‐mTOR, HK2, and pro‐Cas3 in treated HepG2 cells. Overall, these findings provide evidence that CK induces apoptosis via inhibition of glycolysis and AKT/mTOR/c‐Myc signaling in HCC cells as a potent anticancer candidate for liver cancer clinical translation.
科研通智能强力驱动
Strongly Powered by AbleSci AI